Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | MiNa Therapeutics Ltd to present keynote at Oligonucleotide Therapeutics and DeliverySMi reports: SMi are pleased to inform you that Matthew Catley from MiNa Therapeutics Ltd has confirmed his position as speaker
By: SMi Group Matthew will be presenting a keynote on: Small activating RNAs — a novel therapeutic class of oligonucleotide s • Description of saRNA technology to upregulate transcription and broad applicability to a range of therapeutic targets • Generation of a lead candidate saRNA to HNF4a for liver disease • Update on MiNA's lead saRNA clinical agent MTL-CEBPA – Clinical PD and efficacy Dr Matthew Catley completed his PhD studies of airway signalling pathways involved in lung disease with Peter Barnes at Imperial college. He completed further post-doctoral studies on the pharmacology of inhaled therapeutics with Maria Belvisi at Imperial College. Moving to UCB/Celltech he worked on monoclonal antibodies for the treatment of autoimmune and inflammatory disorders. In 2012 he moved to AstraZeneca in Gothenburg to help establish and run the preclinical bioscience department. After a year at Covance, Matthew Joined MiNA therapeutics in 2019 as Research Director. Matthew has developed a range of therapeutic modalities including small molecules, antibodies, peptides and oligonucleotides. The event brochure with the full agenda and speaker line-up is available to download: www.oligonucleotide.co.uk/ Oligonucleotide Therapeutics and Delivery Main conference: 16th – 17th September 2020 London, UK Proudly sponsored by: ChemGenes & TOSOH Bioscience For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088 About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|